All In Biotech

Drug Trial Radar · NCT06394830

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

A Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Jun 2026

Study completion Jun 2026

Sponsor

Lead sponsor
Vaneltix Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Prevail Infoworks
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study drug) to treat acute instances of moderate to severe bladder pain over a 14-day period. The main aim of the study is to tally the number of doses and assess pain before and after doses. The study will review the safety and tolerability of VNX001. Participants will need to attend up to seven (7) clinic visits (1 for screening and up to 6 visits for VNX001 dosing) or at least one (1) clinic visit (for a combined screening/dosing visit) and 5 telephone visits over the course of 14 days. Participants will also be asked complete a diary or telephone call each day of the study, in order to record bladder pain, urinary urgency, side effects, and medications taken.

Conditions

  • Interstitial Cystitis
  • Bladder Pain Syndrome

Interventions

  • VNX001Drug

    Intravesical administration of VNX001

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of PRN intravesical administrations of VNX001Time frame: 14 Days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Urology Specialists

    Tucson, Arizona · Completed

  • Valley Urology, Inc.

    Fresno, California · Suspended

  • Prestige Medical Group

    Tustin, California · Suspended

  • Georgia Urology

    Cartersville, Georgia · Recruiting

  • Oregon Urology Institute

    Springfield, Oregon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.